Boston Scientific Corporation $BSX Stock: MBL Wealth LLC Grows Position

MBL Wealth LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 306.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,191 shares of the medical equipment provider’s stock after acquiring an additional 18,987 shares during the quarter. MBL Wealth LLC’s holdings in Boston Scientific were worth $1,100,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. T3 Companies LLC purchased a new position in Boston Scientific in the third quarter valued at about $232,000. Root Financial Partners LLC purchased a new position in Boston Scientific in the 3rd quarter valued at about $298,000. Crescent Grove Advisors LLC acquired a new stake in shares of Boston Scientific during the 3rd quarter worth about $284,000. Sage Private Wealth Group LLC acquired a new stake in shares of Boston Scientific during the 3rd quarter worth about $479,000. Finally, Kings Path Partners LLC purchased a new stake in shares of Boston Scientific during the third quarter worth about $31,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. UBS Group reduced their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Leerink Partners lowered their target price on shares of Boston Scientific from $60.00 to $55.00 in a research note on Friday, October 9th. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 price target (down from $78.00) on shares of Boston Scientific in a report on Thursday, July 30th. Mizuho set a $55.00 price target on Boston Scientific in a research note on Tuesday, October 13th. Finally, Truist Financial decreased their price objective on Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Trading Down 0.7%

Shares of BSX stock opened at $45.67 on Friday. The firm’s 50-day simple moving average is $45.46 and its 200-day simple moving average is $49.16. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $41.38 and a 1-year high of $105.65. The firm has a market cap of $66.19 billion, a P/E ratio of 18.49, a PEG ratio of 1.11 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts forecast that Boston Scientific Corporation will post 3.24 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney bought 186,240 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 in the last quarter. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.